Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.272 EUR | +0.38% | +1,961.78% | +1,757.39% |
Sales 2024 * | 65.3M 60.06M | Sales 2025 * | 6.25M 5.75M | Capitalization | 20.65M 19M |
---|---|---|---|---|---|
Net income 2024 * | 26M 23.91M | Net income 2025 * | -40M -36.79M | EV / Sales 2024 * | 0.32 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.3 x |
P/E ratio 2024 * |
0.86
x | P/E ratio 2025 * |
-0.54
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on MEI Pharma, Inc.
1 week | +1,961.78% | ||
1 month | +1,710.17% | ||
3 months | +1,373.10% | ||
6 months | +1,042.25% | ||
Current year | +1,757.39% |
Managers | Title | Age | Since |
---|---|---|---|
David Urso
CEO | Chief Executive Officer | 60 | 14-03-06 |
Justin File
DFI | Director of Finance/CFO | 53 | 23-06-11 |
Caroline Ruiz
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 18-02-25 |
Thomas Reynolds
BRD | Director/Board Member | 65 | 13-02-10 |
Charles Baltic
CHM | Chairman | 63 | 11-10-19 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.11% | 63.85B | |
-2.46% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.53% | 26.52B | |
-21.77% | 18.69B | |
+2.73% | 12.73B | |
+21.83% | 12.11B | |
+28.00% | 12.07B |
- Stock Market
- Equities
- MEIP Stock
- MMI0 Stock